Short Interest in INVO Fertility, Inc (NASDAQ:IVF) Declines By 37.8%

INVO Fertility, Inc (NASDAQ:IVF) was the target of a large decline in short interest during the month of January. As of January 15th, there was short interest totaling 41,109 shares, a decline of 37.8% from the December 31st total of 66,048 shares. Currently, 1.7% of the company’s stock are sold short. Based on an average daily trading volume, of 178,991 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily trading volume, of 178,991 shares, the days-to-cover ratio is currently 0.2 days. Currently, 1.7% of the company’s stock are sold short.

INVO Fertility Stock Performance

Shares of NASDAQ IVF opened at $1.41 on Friday. The business’s 50-day simple moving average is $1.32 and its 200-day simple moving average is $6.31. INVO Fertility has a 52 week low of $0.71 and a 52 week high of $141.12. The firm has a market cap of $3.37 million, a price-to-earnings ratio of 0.00 and a beta of 2.60.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of INVO Fertility in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Institutional Trading of INVO Fertility

A hedge fund recently bought a new stake in INVO Fertility stock. Citadel Advisors LLC purchased a new stake in INVO Fertility, Inc (NASDAQ:IVF) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned approximately 1.19% of INVO Fertility as of its most recent SEC filing. Institutional investors and hedge funds own 12.02% of the company’s stock.

INVO Fertility Company Profile

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.